CAM
PGNX

Capstone Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Capstone Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$279K Sell
41,150
-390
-0.9% -$2.88K 0.01% 1312
2017
Q1 		$392K Buy
+41,540
New +$415K 0.01% 1071

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Capstone Asset Management's PGNX Position: Q2 2017 in Review

Capstone Asset Management reduced its Progenics Pharmaceuticals Inc (PGNX) stake by 0.94% in Q2 2017, selling an estimated $2.88K and leaving 41,150 shares worth $279K. The position accounts for 0.01% of the portfolio, ranked #1312.

Capstone Asset Management first reported a position in PGNX in Q1 2017 and has held it in 2 quarters since. The position peaked at $392K in Q1 2017. 152 funds tracked by Wall St. Rank hold PGNX as of Q2 2017.

  • Capstone Asset Management held 41,150 shares of Progenics Pharmaceuticals Inc worth $279K as of Q2 2017.
  • Capstone Asset Management sold 390 Progenics Pharmaceuticals Inc shares in Q2 2017, an estimated $2.88K.
  • Progenics Pharmaceuticals Inc made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1312 holding.
  • Capstone Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and has held it in 2 quarters since.
  • Capstone Asset Management's Progenics Pharmaceuticals Inc position peaked at $392K in Q1 2017.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.